(NASDAQ: TPST) Tempest Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Tempest Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast TPST's revenue for 2027 to be $3,603,640,383, with the lowest TPST revenue forecast at $3,603,640,383, and the highest TPST revenue forecast at $3,603,640,383. On average, 2 Wall Street analysts forecast TPST's revenue for 2028 to be $189,402,184, with the lowest TPST revenue forecast at $82,203,881, and the highest TPST revenue forecast at $296,600,488.
In 2029, TPST is forecast to generate $1,280,380,982 in revenue, with the lowest revenue forecast at $1,280,380,982 and the highest revenue forecast at $1,280,380,982.